David Kirn
Fundador en 4D MOLECULAR THERAPEUTICS, INC. .
Fortuna: 39 M $ al 30/04/2024
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Theresa Janke | F | 49 | 11 años | |
| Scott Bizily | M | 52 | 3 años | |
| Charles Theuer | M | 60 |
The University of California, San Francisco
| 12 años |
| Fariborz Kamal | M | 61 | 6 años | |
| Terry Hermiston | M | - |
Coagulant Therapeutics, Inc.
 Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | 5 años |
| Noriyuki Kasahara | M | 62 | 2 años | |
| Julian Pei | M | - | - | |
| John Milligan | M | 63 | 4 años | |
| Jacob Chacko | M | 45 | 5 años | |
| Shawn Tomasello | F | 65 | 4 años | |
| Bernard J. Taylor | M | 67 |
University of Oxford
| - |
| Nancy Miller-Rich | F | 65 | 4 años | |
| Robert Kim | M | 63 | 2 años | |
| Ian Gardiner | M | - |
University of Oxford
| - |
| Susannah Gray | F | 63 | 4 años | |
| Jinkyun Kim | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| An Song | M | - | 3 años | |
| Anil Razdan | M | 75 |
University of Oxford
| - |
| David A. Larson | M | 83 |
The University of California, San Francisco
| 38 años |
| Won Chul Cho | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| Robin Hanson | M | - |
University of Oxford
| - |
| Stephen Pulman | M | - |
University of Oxford
| - |
| Jan Tadeusz Czernuszka | M | - |
University of Oxford
| - |
| Stefan Karl Neubauer | M | - |
University of Oxford
| - |
| Stephen Westaby | M | - |
University of Oxford
| - |
| Uneek Mehra | M | 51 | 1 años | |
| David Kerr | M | - |
University of Oxford
| - |
| Lars Henrik Fugger | M | 64 |
University of Oxford
| 17 años |
| Zhan Feng Cui | M | 62 |
University of Oxford
| - |
| Mankyu Park | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| Daekyeong Bae | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | 5 años |
| Sheila Barrett | F | - |
University of Oxford
| - |
| Ngaire Woods | F | 62 |
University of Oxford
| 14 años |
| Elish Angiolini | F | - |
University of Oxford
| - |
| J. Doyne Farmer | M | 71 |
University of Oxford
| - |
| David J. Teece | M | 75 |
University of California, Berkeley
| 42 años |
| André Finn | M | - |
University of Oxford
| - |
| Lionel Tarassenko | M | 67 |
University of Oxford
| 27 años |
| Philip E. Wolfson | M | 79 |
The University of California, San Francisco
| 38 años |
| Andrew Wolff | M | 69 |
The University of California, San Francisco
| 38 años |
| Robin Steele | F | 68 |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| Len Blavatnik | M | 66 |
University of Oxford
| - |
| William R. Miller | M | 95 |
University of Oxford
| - |
| James Pennington | M | 81 |
The University of California, San Francisco
| 38 años |
| Ivan M. Lieberburg | M | 74 |
The University of California, San Francisco
| 36 años |
| Crispin Davis | M | 75 |
University of Oxford
| - |
| William Castell | M | 76 |
University of Oxford
| - |
| Lai Kuen Louey | M | 64 |
University of Oxford
| 13 años |
| Soo Min Yeoh | F | 68 |
University of Oxford
| - |
| Patrick Pichette | M | 61 |
University of Oxford
| - |
| André S. Hoffmann | M | 66 |
University of Oxford
| - |
| Simon Boddie | M | 64 |
University of Oxford
| 3 años |
| Jeff Orenstein | M | - |
University of Oxford
| - |
| Julie Baddeley | F | 73 |
University of Oxford
| - |
| Alex Hawker | M | - |
University of Oxford
| - |
| Benjamine Reid | M | - |
University of Oxford
| - |
| Nigel Shadbolt | M | 68 |
University of Oxford
| - |
| Geert Linnebank | M | 68 |
University of Oxford
| - |
| Marc K. Hellerstein | M | 72 |
The University of California, San Francisco
| 37 años |
| Wendy Becker | F | 58 |
University of Oxford
| - |
| John Hagan Pryce Bayley | M | - |
University of Oxford
| 21 años |
| Peter Ratcliffe | M | 69 |
University of Oxford
| - |
| Geoffrey Hale | M | - |
University of Oxford
| - |
| Cheryl Musch | F | - |
University of Oxford
| - |
| Indrajit Wickramasinghe | M | - |
University of Oxford
| - |
| Malcolm McCulloch | M | - |
University of Oxford
| - |
| Jane Green | M | - |
University of Oxford
| - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Qing Huang | M | 62 |
University of California, Berkeley
| 6 años |
| Paul Jacobs | M | 61 |
University of California, Berkeley
| 9 años |
| Kamal H. Khayat | M | - |
University of California, Berkeley
| 7 años |
| Carl Perez | M | - |
University of California, Berkeley
| 8 años |
| David Schaffer | M | 53 | 9 años | |
| Sung Su Han | M | 72 |
University of California, Berkeley
| 12 años |
| Irving Mintzer | M | - |
University of California, Berkeley
| 13 años |
| Fabio Ignazio Romeo | M | 68 |
University of California, Berkeley
| 4 años |
| Adam Rossman | M | 57 |
University of California, Berkeley
| 6 años |
| Nat Simons | M | - |
University of California, Berkeley
| 10 años |
| Wei-Tek Tsai | M | 64 |
University of California, Berkeley
| 5 años |
| Tami S. Smason | F | - |
University of California, Berkeley
| 8 años |
| Richard G. Wallace | M | - |
University of California, Berkeley
| 7 años |
| Ze Xiang Li | M | 63 |
University of California, Berkeley
| 4 años |
| Pierre Breber | M | 59 |
University of California, Berkeley
| 5 años |
| Ray Salomon | M | 61 |
University of California, Berkeley
| 7 años |
| Bahram Nour-Omid | M | - |
University of California, Berkeley
| 4 años |
| Michael J. Estrada | M | - |
University of California, Berkeley
| 3 años |
| Fu Chieh Hsu | M | - |
University of California, Berkeley
| 3 años |
| Thomas E. Bell | M | 75 |
University of California, Berkeley
| 4 años |
| Andreas C. Cangellaris | M | - |
University of California, Berkeley
| 3 años |
| Jaideep Srivastava | M | - |
University of California, Berkeley
| 4 años |
| Sosale Shankara Sastry | M | 68 |
University of California, Berkeley
| 3 años |
| Mark Schena | M | 61 |
The University of California, San Francisco
University of California, Berkeley
| 8 años |
| Gregory M. Heywood | M | 59 |
University of California, Berkeley
| 12 años |
| Thomas E. Tighe | M | - |
University of California, Berkeley
| 7 años |
| Steve Tighe | M | - |
University of California, Berkeley
| 5 años |
| Michael Cima | M | 64 |
University of California, Berkeley
| 8 años |
| Lisa Suennen | F | 58 |
University of California, Berkeley
| 5 años |
| David Choi | M | - |
University of California, Berkeley
| 5 años |
| Eric Stonestrom | M | 62 |
University of California, Berkeley
| 6 años |
| Tony Yao | M | 51 | - | |
| Fabio Romeo | M | - |
University of California, Berkeley
| 4 años |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 60 | 60.00% |
| Reino Unido | 40 | 40.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- David Kirn
- Red Personal
